This infographic explores mavacamten, the first cardiac myosin inhibitor for New York Heart Association (NYHA) Class II and III symptomatic obstructive hypertrophic cardiomyopathy (HCM). Delving into the challenges of HCM as a progressive, chronic disorder, the infographic explores mavacamten’s safety profile, symptom control, and recommended dosing.
The publication of this infographic was supported by Myokardia and Bristol Myers Squibb.
